Syphilis remains an important public health concern due to global case increases. In Australia, the largest syphilis outbreak ever recorded has been ongoing for the last 10 years, and now...
SpeeDx have partnered with researchers from Nepean Hospital in an exclusive agreement to commercialise a molecular test for IFI27 - a host biomarker with expression strongly correlated with disease progression...
The opening of a PC2 laboratory facility at SpeeDx Sydney headquarters is an exciting milestone to celebrate. SpeeDx performs all commercial functions including research, development and manufacturing out of their...
Important clinical data published in Clinical Infectious Diseases demonstrated practical effectiveness of Resistance Guided Therapy for treating gonorrhoea. Led by Dr. Jeffrey Klausner, Professor of epidemiology and medicine at UCLA,...
Important data using ResistancePlus® MG to investigate over 1500 symptomatic vaginitis patients. Mycoplasma genitalium (Mgen) infection was more prevalent in women with bacterial vaginosis (BV) (7.0% Mgen positive) compared with...
Mycoplasma genitalium (Mgen) infections treated using resistance guided therapy led to high cure rates and low levels of de novo resistance, according to latest data from Melbourne Sexual Health published...
The Therapeutic Goods Administration (TGA) have cleared ResistancePlus® MG FleXible for the Cepheid GeneXpert® System, and it is now available for sale in Australia. This announcement further expands access to...
ResistancePlus® MG FleXible for the Cepheid GeneXpert® System is now CE-IVD and available for sale in Europe. The test detects the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers...
This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mycoplasma genitalium (Mgen). Current Canadian management guidelines...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for ResistancePlus® GC - expediting the path towards clearance. This is the first commercially available molecular test that can...